naion semaglutide Once Again Linked to in Largest Study to Date Semaglutide linked to increased risk

SOURCE : CareBareRX Source: CareBareRX

Prescription (if approved) : Not everyone qualifies

This phase 3b trial evaluates mirikizumab combined with tirzepatide versus mirikizumab with a placebo in adult participants with moderately to severely active CD and comorbid obesity (111)

Winlevi (clascoterone, Sun Pharma), approved in August 2020 for hormonal acne, is a good option, Tolkachjov said, as it targets specifically the hormonal type of acne that we think is going on here due to the weight changes. As dermatologists treat GLP-1 receptor agonist-induced acne, Tolkachjov encourages practitioners to communicate this possible side effect to their patients moving forward